Sr. No. |
Title of the Project |
Name of faculty |
Ongoing/ Completed/In pipeline |
1
|
A Randomized Double-Blind, Two arm, Placebo controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infection with COVID-19, Clinical Study Protocol No.: CRSC20005 and A Randomozed, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID19 positive patients hospitalized but not critically ill, Clinical study protocol No.; CRSC20006 |
Dr. P.P. Joshi (PI) Dr Amol Dube (Co-PI) Dr Bharat Rathod (Co-PI) |
Completed |
2 |
Clinical profile and outcomes in COVID 19 suspect/confirmed cases patients |
Dr. P. P. Joshi (PI) |
Completed |
3. |
INDIGENIUS study (CVD-02-CD-002) A randomized open label 2- Treatment Group Clinical trial evaluating the efficacy and safety of 2-Deoxy-D-Glucose as an adjunctive therapy to standard of care in comparison to standard of care in acute treatment of moderate to severe Covid-19 patients. |
Dr. S. Kumbhalkar (PI) |
Completed |
4 |
Efficacy and safety of Ivermectin as an add on therapy to standard in Covid 19- A pilot study |
Dr. P. P. Joshi (PI) Dr. A. H.Dube |
Completed |
5 |
A Randomized open label study to evaluate the efficacy and safety of Favipiravir and Umifenovir as compared to Favipiravir alone in moderate adult Indian Covid-19 patients |
Dr. R. S. Khot (PI) |
Completed |
6 |
Study of serum vitamin D level and its correlation with severity of illness and outcome in COVID-19. |
Dr. B. D. Rathod (PI) |
Completed |
7. |
A Multi-Centre, Prospective, Open Label, Parallel, Randomized, Clinical Trial to Assess the Efficacy And Safety Of Molnupiravir 800 Mg Capsules And Standard of Care (SoC) Compared To Standard of Care (SoC) Only In Mild Patients With Polymerase Chain Reaction (PCR) Confirmed COVID-19 |
Dr. R. S. Khot (PI) |
Completed |
8. |
JIP-MC-KFAJ: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Systemic Lupus Erythematosus |
Dr. R. S. Khot (PI) |
Completed |
9. |
Post Covid symptoms and recovery times in hospitalized Adult Covid 19 patients. |
Dr. R.S. Khot (PI) |
Completed |
10. |
A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19: The “EMPATHY” Trial |
Dr. P. P. Joshi Dr Amol Dube |
Completed |
11 |
A Randomized, Double-blind, parallel Arm, Multicenter Study to Evaluate the Efficacy and Safety of Nitric Oxide Nasal Spray Combined with Standard Supportive Care in Adult non- Hospitalized Patients with COVID-19 |
Dr. S. Kumbhalkar Dr. Bharat Rathod |
On Going |
12 |
A Phase III, Prospective, Randomized, Open Label, Active Controlled, Parallel Group, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination of Vildagliptin and Dapagliflozin Tablets 50mg/5mg of USV Private Limited, India as compared to Concomitant Administration of Reference product, Galvus 50mg tablets (Vidagliptin) of Novartis Pharmaceuticals UK Ltd., along with Forxiga 5mg tablets (Dapagliflozin) of AstraZeneca Pharmaceuticals, USA in patients with type 2 Diabetes Mellitus Inadequately Controlled in earlier metformin containing dual therapy |
Dr. Amol Dube Dr. Prashant P. Joshi Dr. Ganesh Dakhale Dr. Udit Narang |
On Going |
13 |
A phase 3, multicentre, randomized double blind doubledummy, parallel-group active control to compare the efficacy and safety of a fix dose combination of Metformin Hydroclhoride 1000mg ER, Sitagliptin phosphate 100mg and Dapaglifozin propanediol 10mg tablets VS Janumet XRC, combipack of Metformin hydrochloride 1000mg SR and Sitagliptin phosphate 100mg in patients with Type 2 diabetes mellitus (T2DM) |
Dr. Sunita Kumbhalkar Dr. Keshao Nagpure |
On Going |